Literature DB >> 17569882

Increased uridine adenosine tetraphosphate concentrations in plasma of juvenile hypertensives.

Vera Jankowski1, Andreas-Alexander Meyer, Peter Schlattmann, Yu Gui, Xi-long Zheng, Irini Stamcou, Kristina Radtke, Thi Nguyet Anh Tran, Markus van der Giet, Markus Tölle, Walter Zidek, Joachim Jankowski.   

Abstract

BACKGROUND: Uridine adenosine tetraphosphate (Up4A) was been recently characterized as a potent vasoconstrictor. Up4A occurs in plasma from healthy subjects at concentrations sufficient to cause strong vasoconstrictive effects. In this study, Up4A concentrations in plasma from juvenile hypertensives and normotensives were determined. METHODS AND
RESULTS: Up4A was purified to homogeneity by preparative reverse phase high performance liquid-chromatography (HPLC), affinity chromatography HPLC, and analytic reverse phase HPLC from deproteinized plasma of juvenile hypertensives and normotensives. Mean total plasma Up4A concentration was significantly increased in juvenile hypertensives compared with juvenile normotensives (33.0+/-25.4 versus 3.7+/-0.9 nmol/L; mean+/-SEM, n=40 and 38, respectively; P<0.005). Accordingly, Up4A showed a significant association with juvenile hypertension (OR for ln(Up4A): 1.82; 95% CI 1.12, 2.95). Plasma Up4A concentrations correlated with left ventricular mass (Kendall-tau correlation coefficient 0.220, n=40; P<0.05) and intima media wall thickness (Kendall-tau correlation coefficient 0.296, n=40; P<0.05) in the hypertensives. Because the increased intima media thickness may be related to proliferative effects of Up4A, we studied the effects of Up4A on human vascular smooth muscle cell proliferation. The maximum proliferative effect of Up4A was 80.0+/-24.0% % above control (P<0.01). The proliferative effect of Up4A on smooth muscle cells is cell cycle-dependent, involving stimulation of S phase entry.
CONCLUSION: Circulating levels of Up4A are strongly associated with juvenile hypertension. The endothelium-derived vasoconstrictor Up4A may contribute to the early development of primary hypertension and is moreover an important risk factor of juvenile hypertension.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17569882     DOI: 10.1161/ATVBAHA.107.143958

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  22 in total

1.  Alterations in vasoconstrictor responses to the endothelium-derived contracting factor uridine adenosine tetraphosphate are region specific in DOCA-salt hypertensive rats.

Authors:  Takayuki Matsumoto; Rita C Tostes; R Clinton Webb
Journal:  Pharmacol Res       Date:  2011-09-14       Impact factor: 7.658

Review 2.  Increased intima-media thickness of the carotid artery in childhood: a systematic review of observational studies.

Authors:  Christophe Lamotte; Catalina Iliescu; Christian Libersa; Frédéric Gottrand
Journal:  Eur J Pediatr       Date:  2010-10-27       Impact factor: 3.183

Review 3.  Dinucleoside polyphosphates: strong endogenous agonists of the purinergic system.

Authors:  Vera Jankowski; Markus van der Giet; Harald Mischak; Michael Morgan; Walter Zidek; Joachim Jankowski
Journal:  Br J Pharmacol       Date:  2009-06-25       Impact factor: 8.739

Review 4.  Constrictor prostanoids and uridine adenosine tetraphosphate: vascular mediators and therapeutic targets in hypertension and diabetes.

Authors:  Takayuki Matsumoto; Styliani Goulopoulou; Kumiko Taguchi; Rita C Tostes; Tsuneo Kobayashi
Journal:  Br J Pharmacol       Date:  2015-07-08       Impact factor: 8.739

5.  The endothelium-derived contracting factor uridine adenosine tetraphosphate induces P2Y(2)-mediated pro-inflammatory signaling by monocyte chemoattractant protein-1 formation.

Authors:  Mirjam Schuchardt; Jasmin Prüfer; Nicole Prüfer; Annette Wiedon; Tao Huang; Miriam Chebli; Vera Jankowski; Joachim Jankowski; Monika Schäfer-Korting; Walter Zidek; Markus van der Giet; Markus Tölle
Journal:  J Mol Med (Berl)       Date:  2011-04-13       Impact factor: 4.599

6.  Uridine adenosine tetraphosphate is a novel neurogenic P2Y1 receptor activator in the gut.

Authors:  Leonie Durnin; Sung Jin Hwang; Masaaki Kurahashi; Bernard T Drumm; Sean M Ward; Kent C Sasse; Kenton M Sanders; Violeta N Mutafova-Yambolieva
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-23       Impact factor: 11.205

Review 7.  Uridine adenosine tetraphosphate and purinergic signaling in cardiovascular system: An update.

Authors:  Zhichao Zhou; Takayuki Matsumoto; Vera Jankowski; John Pernow; S Jamal Mustafa; Dirk J Duncker; Daphne Merkus
Journal:  Pharmacol Res       Date:  2018-12-13       Impact factor: 7.658

8.  Mechanisms underlying uridine adenosine tetraphosphate-induced vascular contraction in mouse aorta: Role of thromboxane and purinergic receptors.

Authors:  Zhichao Zhou; Changyan Sun; Stephen L Tilley; S Jamal Mustafa
Journal:  Vascul Pharmacol       Date:  2015-04-25       Impact factor: 5.773

9.  Enhanced uridine adenosine tetraphosphate-induced contraction in renal artery from type 2 diabetic Goto-Kakizaki rats due to activated cyclooxygenase/thromboxane receptor axis.

Authors:  Takayuki Matsumoto; Shun Watanabe; Ryusuke Kawamura; Kumiko Taguchi; Tsuneo Kobayashi
Journal:  Pflugers Arch       Date:  2013-07-31       Impact factor: 3.657

10.  Uridine adenosine tetraphosphate-induced contraction is increased in renal but not pulmonary arteries from DOCA-salt hypertensive rats.

Authors:  Takayuki Matsumoto; Rita C Tostes; R Clinton Webb
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-05-06       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.